MicroRNA‑432 is downregulated in cervical cancer and directly targets FN1 to inhibit cell proliferation and invasion

Wang,Shanzong; Gao,Baohong; Yang,Hailin; Liu,Xuejian; Wu,Xia; Wang,Weijuan

doi:10.3892/ol.2019.10403

MicroRNA‑432 is downregulated in cervical cancer and directly targets FN1 to inhibit cell proliferation and invasion

Authors:
- Shanzong Wang
- Baohong Gao
- Hailin Yang
- Xuejian Liu
- Xia Wu
- Weijuan Wang
View Affiliations

Affiliations: Department of Pathology, The Third People's Hospital of Linyi, Linyi, Shandong 276023, P.R. China, Department of Gynecology, The Third People's Hospital of Linyi, Linyi, Shandong 276023, P.R. China, Department of Oncology, The Third People's Hospital of Linyi, Linyi, Shandong 276023, P.R. China
Published online on: May 27, 2019 https://doi.org/10.3892/ol.2019.10403
Pages: 1475-1482

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Numerous studies have identified the dysregulation of microRNAs (miRNAs) in cervical cancer, and dysregulated miRNAs are involved in regulating a number of tumour‑associated biological behaviours. Therefore, investigating the roles of cervical cancer‑associated miRNAs and the underlying molecular mechanisms is essential for the development of novel diagnostic biomarkers and effective therapeutic targets. MicroRNA‑432 (miR‑432) dysregulation has been revealed to be implicated in the carcinogenesis and progression of a number of types of human cancer. However, the effects and underlying molecular mechanisms of miR‑432 in cervical cancer have yet to be elucidated. In the present study, miR‑432 expression was determined using reverse transcription‑quantitative polymerase chain reaction. The results revealed that miR‑432 was expressed at low levels in cervical cancer tissues and cell lines. Decreased miR‑432 expression was significantly associated with the International Federation of Gynecology and Obstetrics stage, myometrium invasion and lymph node metastasis of patients with cervical cancer. Following transfection with miR‑432 mimic, the expression of miR‑432 was significantly upregulated in cervical cancer cells. Upregulation of miR‑432 expression restricted the proliferation and invasion of cervical cancer cells. Bioinformatics analysis followed by luciferase reporter assays revealed that fibronectin 1 (FN1) was a direct target gene of miR‑432 in cervical cancer cells. In addition, FN1 was upregulated in cervical cancer tissues and was inversely correlated with miR‑432 levels. Furthermore, miR‑432 upregulation decreased the expression levels of FN1 in cervical cancer cells at the mRNA and protein levels. Furthermore, silencing of FN1 could stimulate the tumour suppressor effects of miR‑432 upregulation in cervical cancer cells. In addition, restored FN1 expression neutralized the effects of miR‑432 overexpression in cervical cancer cells. The results of the present study indicate that miR‑432 is a tumour suppressor that can restrain the aggressive phenotype of cervical cancer cells by directly targeting FN1, suggesting that this miRNA may be developed as an effective therapeutic strategy for patients with cervical cancer.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Banno K, Iida M, Yanokura M, Kisu I, Iwata T, Tominaga E, Tanaka K and Aoki D: MicroRNA in cervical cancer: OncomiRs and tumor suppressor miRs in diagnosis and treatment. ScientificWorldJournal 2014. 1780752014.
3	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
4	Handler AS, Henderson VA, Rosenfeld A, Rankin K, Jones B and Issel LM: Illinois breast and cervical cancer program: Implementing effective public-private partnerships to assure population health. J Public Health Manag Pract. 21:459–466. 2015. View Article : Google Scholar : PubMed/NCBI
5	Kogo R, How C, Chaudary N, Bruce J, Shi W, Hill RP, Zahedi P, Yip KW and Liu FF: The microRNA-218~Survivin axis regulates migration, invasion, and lymph node metastasis in cervical cancer. Oncotarget. 6:1090–1100. 2015. View Article : Google Scholar : PubMed/NCBI
6	Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A and Enright AJ: miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 34:D140–D144. 2006. View Article : Google Scholar : PubMed/NCBI
7	Shu L, Zhang Z and Cai Y: MicroRNA-204 inhibits cell migration and invasion in human cervical cancer by regulating transcription factor 12. Oncol Lett. 15:161–166. 2018.PubMed/NCBI
8	Srivastava SK, Ahmad A, Zubair H, Miree O, Singh S, Rocconi RP, Scalici J and Singh AP: MicroRNAs in gynecological cancers: Small molecules with big implications. Cancer Lett. 407:123–138. 2017. View Article : Google Scholar : PubMed/NCBI
9	Zhao Y, Liu X and Lu YX: MicroRNA-143 regulates the proliferation and apoptosis of cervical cancer cells by targeting HIF-1alpha. Eur Rev Med Pharmacol Sci. 21:5580–5586. 2017.PubMed/NCBI
10	Zhang H, Lu Y, Wang S, Sheng X and Zhang S: MicroRNA-152 acts as a tumor suppressor microRNA by inhibiting Kruppel-like factor 5 in human cervical cancer. Oncol Res. 27:335–340. 2019. View Article : Google Scholar : PubMed/NCBI
11	Gong M, Chen C, Zhao H, Sun M and Song M: miR-506 suppresses cervical cancer cell proliferation both in vitro and in vivo. Neoplasma. 65:331–338. 2018. View Article : Google Scholar : PubMed/NCBI
12	Zhang Z, Wang J, Wang X, Song W, Shi Y and Zhang L: MicroRNA-21 promotes proliferation, migration, and invasion of cervical cancer through targeting TIMP3. Arch Gynecol Obstet. 297:433–442. 2018. View Article : Google Scholar : PubMed/NCBI
13	Yu LM, Wang WW, Qi R, Leng TG and Zhang XL: MicroRNA-224 inhibition prevents progression of cervical carcinoma by targeting PTX3. J Cell Biochem. 119:10278–10290. 2018. View Article : Google Scholar : PubMed/NCBI
14	Chen Z, Zhang M, Qiao Y, Yang J and Yin Q: MicroRNA-1297 contributes to the progression of human cervical carcinoma through PTEN. Artif Cells Nanomed Biotechnol. 46 (Suppl 2):S1120–S1126. 2018. View Article : Google Scholar
15	Kanekura K, Nishi H, Isaka K and Kuroda M: MicroRNA and gynecologic cancers. J Obstet Gynaecol Res. 42:612–617. 2016. View Article : Google Scholar : PubMed/NCBI
16	Gonzalez-Quintana V, Palma-Berré L, Campos-Parra AD, López-Urrutia E, Peralta-Zaragoza O, Vazquez-Romo R and Pérez-Plasencia C: MicroRNAs are involved in cervical cancer development, progression, clinical outcome and improvement treatment response (Review). Oncol Rep. 35:3–12. 2016. View Article : Google Scholar : PubMed/NCBI
17	Wang F, Li B and Xie X: The roles and clinical significance of microRNAs in cervical cancer. Histol Histopathol. 31:131–139. 2016.PubMed/NCBI
18	Chen L, Kong G, Zhang C, Dong H, Yang C, Song G, Guo C, Wang L and Yu H: MicroRNA-432 functions as a tumor suppressor gene through targeting E2F3 and AXL in lung adenocarcinoma. Oncotarget. 7:20041–20053. 2016.PubMed/NCBI
19	Das E and Bhattacharyya NP: MicroRNA-432 contributes to dopamine cocktail and retinoic acid induced differentiation of human neuroblastoma cells by targeting NESTIN and RCOR1 genes. FEBS Lett. 588:1706–1714. 2014. View Article : Google Scholar : PubMed/NCBI
20	Jiang N, Chen WJ, Zhang JW, Xu C, Zeng XC, Zhang T, Li Y and Wang GY: Downregulation of miR-432 activates Wnt/beta-catenin signaling and promotes human hepatocellular carcinoma proliferation. Oncotarget. 6:7866–7879. 2015.PubMed/NCBI
21	Li JB, Liu F, Zhang BP, Bai WK, Cheng W, Zhang YH and Yu LJ: LncRNA625 modulates prostate cancer cells proliferation and apoptosis through regulating the Wnt/beta-catenin pathway by targeting miR-432. Eur Rev Med Pharmacol Sci. 21:2586–2595. 2017.PubMed/NCBI
22	Guo L, Liu X, Wang L, Sun H, Huang K, Li X, Tang F, Li S, Yuan X and Wang C: Outcome of international Federation of gynecology and obstetrics stage IIb cervical cancer from 2003 to 2012: An evaluation of treatments and prognosis: A retrospective study. Int J Gynecol Cancer. 25:910–918. 2015. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Cai X, Liu C, Zhang TN, Zhu YW, Dong X and Xue P: Down-regulation of FN1 inhibits colorectal carcinogenesis by suppressing proliferation, migration, and invasion. J Cell Biochem. 119:4717–4728. 2018. View Article : Google Scholar : PubMed/NCBI
25	Ye Y, Zhuang J, Wang G, He S, Ni J and Xia W: MicroRNA-139 targets fibronectin 1 to inhibit papillary thyroid carcinoma progression. Oncol Lett. 14:7799–7806. 2017.PubMed/NCBI
26	Wang J, Deng L, Huang J, Cai R, Zhu X, Liu F, Wang Q, Zhang J and Zheng Y: High expression of Fibronectin 1 suppresses apoptosis through the NF-κB pathway and is associated with migration in nasopharyngeal carcinoma. Am J Transl Res. 9:4502–4511. 2017.PubMed/NCBI
27	Xu X, Liu Z, Zhou L, Xie H, Cheng J, Ling Q, Wang J, Guo H, Wei X and Zheng S: Characterization of genome-wide TFCP2 targets in hepatocellular carcinoma: Implication of targets FN1 and TJP1 in metastasis. J Exp Clin Cancer Res. 34:62015. View Article : Google Scholar : PubMed/NCBI
28	Diaz-Gonzalez Sdel M, Deas J, Benitez-Boijseauneau O, Gómez-Cerón C, Bermúdez-Morales VH, Rodríguez-Dorantes M, Pérez-Plasencia C and Peralta-Zaragoza O: Utility of microRNAs and siRNAs in cervical carcinogenesis. Biomed Res Int 2015. 3749242015.
29	Yang F, Guo L, Cao Y, Li S, Li J and Liu M: MicroRNA-7-5p promotes cisplatin resistance of cervical cancer cells and modulation of cellular energy homeostasis by regulating the expression of the PARP-1 and BCL2 genes. Med Sci Monit. 24:6506–6516. 2018. View Article : Google Scholar : PubMed/NCBI
30	Shang A, Zhou C, Bian G, Chen W, Lu W, Wang W and Li D: miR-381-3p restrains cervical cancer progression by downregulating FGF7. J Cell Biochem. 120:778–789. 2019. View Article : Google Scholar : PubMed/NCBI
31	Ruiz-Garcia E, Scott V, Machavoine C, Bidart JM, Lacroix L, Delaloge S and Andre F: Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening. Br J Cancer. 102:462–468. 2010. View Article : Google Scholar : PubMed/NCBI
32	Zhang H, Sun Z, Li Y, Fan D and Jiang H: MicroRNA-200c binding to FN1 suppresses the proliferation, migration and invasion of gastric cancer cells. Biomed Pharmacother. 88:285–292. 2017. View Article : Google Scholar : PubMed/NCBI
33	Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PC, van der Burg ME, Stoter G, et al: Molecular profiling of platinum resistant ovarian cancer. Int J Cancer. 118:1963–1971. 2006. View Article : Google Scholar : PubMed/NCBI
34	Sponziello M, Rosignolo F, Celano M, Maggisano V, Pecce V, De Rose RF, Lombardo GE, Durante C, Filetti S, Damante G, et al: Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells. Mol Cell Endocrinol. 431:123–132. 2016. View Article : Google Scholar : PubMed/NCBI